March 22, 2016 5:46pm
The stem, cell and gene therapy and regenerative medicine sector gave up only meager gains inattentive to evidence of flat lining sentiment
Ranking Tuesday’s end-of-day pre-open trading indications – 2 hits and 3 misses – always be aware of commentary that is “early”.
Subscribe: http://www.regmedinvestors.com/create-account
There is one thing that everyone needs, and that's interpretation and translation of intelligence, not just news or information - we get too much!
- To that end, I report a matrix of variables designed for investor’s consideration concerning the stem, cell and gene therapy regenerative medicine portfolio to track and monitor its pricing metric;
The takeaway is that investor need to decide what actions to take, or not take, based on their specific situation.
U.S. stocks closed mixed Tuesday after opening lower amid news of explosions in Belgium's capital that killed more than two dozen people at the airport and metro system.
The NASDAQ closed UP +12.79 or +0.27% to 4,821.66 and the DOW closed DOWN -41.30 or -0.23% to 17,582.57.
A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector – the advance/decline line scenario of our 43 covered companies.
- Tuesday, the stem, cell and gene therapy RegMed sector opened positive with an A/DL of 26/14 and 3 flats;
- The mid-day stayed positive with an A/DL of 22/19 and 2 flats;
- The closing bell rang positive with A/DL of 26/15 and 2 flat
Earnings update:
- Regenerative Medicine Earnings Scorecard - Q4/2015 - to date … http://www.regmedinvestors.com/articles/8876
Henry’omics:
The stem, cell and gene therapy regenerative medicine (SCGT&RM) sector opened positive, stayed positive at the mid-day and closed … positive (of 43 covered companies).
- After a terrible day in Brussels, “our” universe was not adversely affected like the US markets which were a “bit” off but, not crashing; after last week where you had quadruple witching, there's really not a whole lot going on this week with Good Friday and Easter being off.
The Volatility Index (VIX), widely considered the best gauge of fear in the market, traded just above 14, hasn’t been bad having remained pretty flat for the past four (4) sessions.
- Reiterating, MY warning that the SCGT&RM sector is not as strong – as yesterday’s and today’s share pricing has NOT hit as I had expected but, I am NOT changing my view of potential trouble ahead.
Second reiteration, the moment a bit of weakness appears or imposes itself upon the sector – be ready! Short-term deterioration is in the wind and ready to blow-down some appreciation!
Notice:
- That the advance/decline line scenario <above> of our 43 covered companies are declining from yesterday;
- The Russell 2000 (IWM) also closed DOWN on Tuesday -0.13 or -0.12% following Monday’s decline of -0.26 or -0.24%
Until then …
Tuesday’s handicapping the sector pre-open indications – 2 hits and 3 miss:
- Applied Genetic Technologies (AGTC) closed DOWN -$0.06 – hit;
- Bellicum Pharma (BLCM) closed UP +$0.15 – miss;
- Capricor (CAPR) closed UP +$0.20 – miss;
- Kite Pharma (KITE) closed DOWN -$0.38 – hit;
- Vericel (VCEL) closed UP +$0.08 – miss;
Dosing the sector – what a day for the 43 Patients:
- The market opened: POSITIVE with 14 decliners, 26 advancers and 3 flats;
- The mid-day (12:30 pm: POSITIVE with 19 decliners, 22 advancers and 2 flat;
- Closing bell: POSITIVE with 15 decliners, 26 advancers and 2 flats
Review my fear gauge or the CBOE Volatility Index (VIX) which is scary:
- Tuesday traded above 14;
- Monday traded near 14;
- Friday above 14;
- Thursday traded below 14;
- Wednesday traded below 15.5;
- Last, Tuesday traded above 17;
Riding the indexes and ETFs roller-coaster:
The iShares Biotechnology Stocks ETF (IBB) closed UP on Tuesday +6.61 or +2.58%
- Monday +5.15 or +2.05%
- Friday +4.25 or +1.72%
- Thursday -3.11 or -1.24%
- Wednesday -1.27 or -0.51%
- Last, Tuesday -9.97 or -3.81%
The NASDAQ Biotechnology index (NBI) closed UP on Tuesday +69.98 or +2.61%
- Monday +50.02 or +1.90%
- Friday +46.39 or +1.80%
- Thursday -31.69 or -1.21%
- Wednesday -13.26 or -0.50%
- Last, Tuesday -105.31 or -3.85%
The Russell 2000 (IWM) closed DOWN on Tuesday -0.13 or -0.12%
- Monday -0.26 or -0.24%
- Friday +0.98 or +0.90%
- Thursday +1.64 or +1.53%
- Wednesday +1.75 or +0.71
- Last, Tuesday -1.68 or -1.56%
The SPDR SD&P Biotech ETF (XBI) closed UP on Tuesday +1.66 or +3.27%
- Monday +1.18 or +2.38
- Friday was up;
- Thursday +0.16 or +0.33%
- Wednesday -0.58 or -1.19%
- Last, Tuesday -3.00 or -5.78%
Who was leading the declines – to of the bottom 5?
- Intrexon (XON) closed down -$0.64 to $37.80;
- Kite Pharma (KITE) -$0.38 to $45.45;
- Mesoblast (MESO) -$0.31 to $9.45;
- International Stem cell (ISCO) -$0.20 to $3.78;
- Asterias Biotherapeutics (NYSEMKT: AST) closed down -$0.15 to $5.08
Who was UP – top 5:
- bluebird bio (BLUE) closed UP +$2.09 to $46.11;
- Spark Therapeutics (ONCE) +$2.01 to $36.95;
- Juno Therapeutics (JUNO) +$1.36 to $40.50;
- uniQure (QURE) +$0.71 to $12.70;
- Aduro Biotech (ADRO) closed up +$0.50 to $13.07
Who was FLAT?
- ReNeuron (RENE.L) at $3.375;
- VistaGen (VSTA) at $7.99
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
